Tumor Acidity-Activated R9 Peptide Nanocarrier Delivers Drugs Selectively to Cancer Cells
A polymeric nanocarrier with acid-activated R9 cell-penetrating peptide selectively delivers drugs at tumor pH (~6.5), significantly enhancing anti-tumor efficacy in mice.
Quick Facts
What This Study Found
Tumor acidity-activatable polyanionic coating deshielded at pH 6.5, re-exposing R9 peptide and significantly increasing intracellular drug concentration in tumor cells. The system remarkably promoted anti-tumor efficiency in tumor-bearing mice.
Key Numbers
R9 activated at tumor pH (~6.5); inactive at normal pH (7.4); selective tumor uptake in vivo.
How They Did This
Fabrication of PEG-PHEP-R9 nanoparticles coated with pH-responsive polyanionic polyphosphoester. In vitro uptake studies at pH 7.4 vs 6.5 in 4T1 cells. In vivo anti-tumor efficacy in tumor-bearing mice.
Why This Research Matters
Tumor selectivity is the holy grail of cancer drug delivery. By exploiting the universal feature of tumor acidity to control drug release, this system could reduce off-target toxicity while increasing drug concentration at the tumor.
The Bigger Picture
Smart drug delivery systems that respond to the tumor microenvironment represent a growing field. pH-responsive systems exploit one of the most reliable differences between tumor and normal tissue, making them broadly applicable across cancer types.
What This Study Doesn't Tell Us
Tested in a single tumor model (4T1). pH variations within tumors may affect consistency of activation. Manufacturing complexity of multi-layer nanoparticles could challenge clinical translation.
Questions This Raises
- ?How does this system perform across different tumor types with varying acidity levels?
- ?Can the pH activation threshold be tuned for different clinical applications?
- ?What is the safety profile of the polymer components in long-term use?
Trust & Context
- Key Stat:
- pH 6.5 tumor acidity threshold that activates R9 peptide for selective cancer cell drug uptake
- Evidence Grade:
- Proof-of-concept with in vitro mechanism confirmation and in vivo efficacy data. Single tumor model limits generalizability.
- Study Age:
- Published in 2020. pH-responsive drug delivery systems continue to advance toward clinical testing.
- Original Title:
- A polymeric nanocarrier with a tumor acidity-activatable arginine-rich (R9) peptide for enhanced drug delivery.
- Published In:
- Biomaterials science, 8(8), 2255-2263 (2020)
- Authors:
- Zhang, Liting(2), Jiang, Chengtao, Zeng, Fanjun, Zhou, Haiyu, Li, Dongdong, He, Xinyu, Shen, Song, Yang, Xianzhu, Wang, Jun
- Database ID:
- RPEP-05231
Evidence Hierarchy
Frequently Asked Questions
Why are tumors acidic?
Cancer cells produce large amounts of lactic acid through rapid metabolism, making the tumor environment slightly more acidic (pH ~6.5) than normal tissue (pH ~7.4). This pH difference can be exploited for targeted drug delivery.
What is an R9 peptide?
R9 is a cell-penetrating peptide made of nine arginine amino acids. It's very effective at getting into cells, but normally enters all cells indiscriminately. This system activates R9 only at tumor sites.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05231APA
Zhang, Liting; Jiang, Chengtao; Zeng, Fanjun; Zhou, Haiyu; Li, Dongdong; He, Xinyu; Shen, Song; Yang, Xianzhu; Wang, Jun. (2020). A polymeric nanocarrier with a tumor acidity-activatable arginine-rich (R9) peptide for enhanced drug delivery.. Biomaterials science, 8(8), 2255-2263. https://doi.org/10.1039/d0bm00069h
MLA
Zhang, Liting, et al. "A polymeric nanocarrier with a tumor acidity-activatable arginine-rich (R9) peptide for enhanced drug delivery.." Biomaterials science, 2020. https://doi.org/10.1039/d0bm00069h
RethinkPeptides
RethinkPeptides Research Database. "A polymeric nanocarrier with a tumor acidity-activatable arg..." RPEP-05231. Retrieved from https://rethinkpeptides.com/research/zhang-2020-a-polymeric-nanocarrier-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.